Suchergebnisse - "Wiemann, Stefan"

PubPharm (164)

1

Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands

enthalten in: The American journal of surgical pathology | 2019

von Haller, F. | Skálová, A. | Ihrler, S. | +15

CommentIn: Am J Surg Pathol. 2019 Dec;43(12):1726-1728. - PMID 31414988

2

Reconstruction of Different Modes of WNT Dependent Protein Networks from Time Series Protein Quantification

enthalten in: Studies in health technology and informatics | 2019

von Sitte, M. | Menck, K. | Wachter, A. | +5

3

Assembly of a parts list of the human mitotic cell cycle machinery

enthalten in: Journal of molecular cell biology | 2019

von Giotti, B. | Chen, S. | Barnett, M. | +5

4

Identification and prioritisation of causal variants in human genetic disorders from exome or whole genome sequencing data

enthalten in: bioRxiv.org | 2019

von Paramasivam, N. | Granzow, M. | Evers, C. | +5

5

Functional Proteomics of Breast Cancer Metabolism Identifies GLUL as Responder during Hypoxic Adaptation

enthalten in: Journal of proteome research | 2019

von Bernhardt, S. | Tönsing, C. | Mitra, D. | +6

6

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer

enthalten in: Frontiers in immunology | 2019

von Liubomirski, Y. | Lerrer, S. | Meshel, T. | +7

7

Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands

enthalten in: Nature communications | 2019

von Haller, F. | Bieg, M. | Will, R. | +20

8

Functional proteomics of breast cancer metabolism identifies GLUL as responder during hypoxic adaptation

enthalten in: Journal of proteome research | January 4, 2019

von Bernhardt, S. | Müller-Decker, K. | Wiemann, S.

9

Identification of the receptor B7-H3

Erschienen: Dissertation, Ruperto-Carola University of Heidelberg, 2019

von Ciprut, S. | Wiemann, S.

10

Vorhabenbezeichnung: e:Med - Modul II - Verbundprojekt: HER2Low - Mathematische Modellierung der Wirkungsweise von gegen HER2, EGFR und ERBB3 gerichteten therapeutischen Antikörpern zur Personalisierung der Brustkrebstherapie : Schlussbericht zu Teilprojekt 4-1 : Laufzeit des Vorhabens 01.03.2015-31.12.2018 = HER2Low: Targeting the ERBB-module in HER2-low breast cancer: Mathematical modeling of response towards drugs targeting HER2, EGFR and ERBB3 to personalize breast cancer treatment

Erschienen: [Heidelberg], Deutsches Krebsforschungszentrum (DKFZ), [2019?]

von Wiemann, S.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]